Vasopressin: A Review of Therapeutic Applications

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 24, Issue 2, 2010, Pages 330-347

  Holt, Natalie F ^a,b   Haspel, Kenneth L ^a,b  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

antidiuretic hormone; arginine vasopressin; vaptans; vasopressin; vasopressors

Indexed keywords

1 [5 CHLORO 1 (2,4 DIMETHOXYLPHENYLSULFONYL) 2,3 DIHYDRO 3 (2 METHOXYPHENYL) 2 OXO 1H INDOL 3 YL] 4 HYDROXY N,N DIMETHYL 2 PYRROLIDINECARBOXAMIDE; ADRENALIN; ANESTHETIC AGENT; CARBAMAZEPINE; CONIVAPTAN; CORTICOSTEROID DERIVATIVE; CORTICOTROPIN; CYCLOPHOSPHAMIDE; DEMECLOCYCLINE; DESMOPRESSIN; LIXIVAPTAN; NEUROPHYSIN; NICOTINE; PHENOTHIAZINE DERIVATIVE; RELCOVAPTAN; TERLIPRESSIN; TOLVAPTAN; TRICYCLIC ANTIDEPRESSANT AGENT; VASOPRESSIN; VASOPRESSIN ANTAGONIST; VASOPRESSIN V1 RECEPTOR; VASOPRESSIN V2 RECEPTOR; VASOPRESSIN V3 RECEPTOR; VINCRISTINE; HYPOTHALAMUS HORMONE; VASOPRESSIN DERIVATIVE;

ABDOMINAL DISTENSION; BEDTIME DOSAGE; BILE FLOW; BLEEDING; CARDIOPULMONARY BYPASS; CIRCADIAN RHYTHM; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; DIABETES INSIPIDUS; DRUG DOSE TITRATION; DRUG INDICATION; DYSMENORRHEA; EPIDURAL ANESTHESIA; ESOPHAGUS VARICES BLEEDING; FETUS MALFORMATION; HEART ARREST; HEART INDEX; HEART MUSCLE ISCHEMIA; HEMOPHILIA A; HEMORRHAGIC SHOCK; HEPATORENAL SYNDROME; HORMONE SYNTHESIS; HUMAN; HYPONATREMIA; HYPOTENSION; HYPOTHALAMUS PERIVENTRICULAR NUCLEUS; INAPPROPRIATE VASOPRESSIN SECRETION; LIMB ISCHEMIA; LIVER CIRRHOSIS; MENIERE DISEASE; NEUROHYPOPHYSIS; NOCTURNAL ENURESIS; NONHUMAN; PERIOPERATIVE COMPLICATION; POLYURIA; PREMATURE LABOR; PRESSORECEPTOR; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RANDOMIZED CONTROLLED TRIAL; RAYNAUD PHENOMENON; REVIEW; SEPTIC SHOCK; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN NECROSIS; SUPRAOPTIC NUCLEUS; THIRST; THROMBOCYTE DYSFUNCTION; THROMBOCYTOPENIA; TREATMENT DURATION; VASOPRESSIN RELEASE; VON WILLEBRAND DISEASE; XEROSTOMIA; ANIMAL; BLOOD; CARDIOVASCULAR DISEASES; DRUG EFFECTS; OSMOLARITY; PHYSIOLOGY;

ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; HYPOTHALAMIC HORMONES; OSMOLAR CONCENTRATION; SIGNAL TRANSDUCTION; VASOPRESSINS;

EID: 77950043913     PISSN: 10530770     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jvca.2009.09.006     Document Type: Review

References (292)

1. Oliver G., and Schaefer E. On the physiological action of extract of pituitary body and certain other glandular organs. J Physiol 18 (1895) 277-279
2. Dekanski J. The quantitative assay of vasopressin. Br J Pharmacol Chemother 7 (1952) 567-572
3. Du Vigneaud V., Gish D., and Katsoyannis P. A synthetic preparation possessing biological properties associated with arginine-vasopressin. J Am Chem Soc 76 (1954) 4751-4752
4. Vincent J., and Su F. Physiology and pathophysiology of the vasopressinergic system. Best Pract Res Clin Anaesthesiol 22 (2008) 243-252
5. Maybauer M., Maybauer D., Enkhbaatar P., et al. Physiology of the vasopressin receptors. Best Pract Res Clin Anaesthesiol 22 (2008) 253-263
6. Bankir L. Antidiuretic action of vasopressin: Quantitative aspects of interaction between V1a and AV3 receptor-mediated effects. Cardiovasc Res 51 (2001) 372-390
7. Williams T., Da Costa D., Mathias C., et al. Pressor effect of arginine vasopressin in progressive autonomic failure. Clin Sci (Lond) 71 (1986) 173-178
8. Baylis P. Osmoregulation and control of vasopressin secretion in healthy humans. Am J Physiol 253 (1987) R671-R678
9. Leng G., Brown C., and Russell J. Physiological pathways regulating the activity of magnocellular neurosecretory cells. Prog Neurobiol 57 (1999) 625-655
10. Bielsky I., Hu S., Ren X., et al. The V1a vasopressin receptor is necessary and sufficient for normal social recognition: A gene replacement study. Neuron 47 (2005) 503-513
11. Weingartner H., Gold P., Ballenger J., et al. Effects of vasopressin on human memory functions. Science 211 (1981) 601-603
12. George C., Messerli F., Genest J., et al. Diurnal variation of plasma vasopressin in man. J Clin Endocrinol Metab 41 (1975) 332-338
13. Treschan T.A., and Peters J. The vasopressin system: Physiology and clinical strategies. Anesthesiology 105 (2006) 599-612
14. Holmes C., Patel B., Russell J., et al. Physiology of vasopressin relevant to management of septic shock. Chest 120 (2001) 989-1002
15. Sklar A., and Schrier R. Central nervous system mediators of vasopressin release. Physiol Rev 63 (1983) 1243-1280
16. Baumann G., and Dingman J. Distribution, blood transport, and degradation of antidiuretic hormone. J Clin Invest 57 (1976) 1109-1116
17. Beardwell C., Geelen G., Palmer H., et al. Radioimmunoassay of plasma vasopressin in physiological and pathological states in man. J Endocrinol 67 (1975) 189-202
18. Aki Y., Tamaki T., Kiyomoto H., et al. Nitric oxide may participate in V2 vasopressin-receptor-mediated renal vasodilation. J Cardiovasc Pharmacol 23 (1994) 331-333
19. Hasser E., Cunnningham J., Sullivan M., et al. Area postrema and sympathetic nervous system effects of vasopressin and angiotensin II. Clin Exp Pharmacol Physiol 27 (2000) 432-436
20. Grindstaff R., and Cunningham J. Cardiovascular regulation of vasopressin neurons in the supraoptic nucleus. Exp Neurol 171 (2001) 219-226
21. Frank E., and Landgraf R. The vasopressin system-From antidiuresis to psychopathology. Eur J Pharmacol 583 (2008) 226-242
22. Mannucci P.M. Desmopressin: an historical introduction. Haemophilia 14 suppl 1 (2008) 1-4
23. Thibonnier M., Preston J., Dulin N., et al. The human V3 pituitary vasopressin receptor: Ligand binding profile and density-dependent signaling pathways. Endocrinology 138 (1997) 4109-4122
24. Lauzier F., Levy B., Lamarre P., et al. Vasopressin or norepinephrine in early hyperdynamic septic shock: A randomized clinical trial. Intensive Care Med 32 (2006) 1782-1789
25. Kornberger E., Prengel A.W., Krismer A., et al. Vasopressin-mediated adrenocorticotropin release increases plasma cortisol concentrations during cardiopulmonary resuscitation. Crit Care Med 28 (2000) 3517-3521
26. Katoh K., Yoshida M., Kobayashi Y., et al. Responses induced by arginine-vasopressin injection in the plasma concentrations of adrenocorticotropic hormone, cortisol, growth hormone and metabolites around weaning time in goats. J Endocrinol 187 (2005) 249-256
27. Cogan E., Debiève M., Philipart I., et al. High plasma levels of atrial natriuretic factor in SIADH. N Engl J Med 314 (1986) 1258-1259
28. Meller W., Lewis D., Gehris T., et al. Human anterior pituitary response to exogenous arginine vasopressin. Acta Endocrinol (Copenh) 125 (1991) 378-384
29. Balakrishnan S., Gopalakrishnan V., and McNeill J. Endothelin contributes to the hemodynamic effects of vasopressin in spontaneous hypertension. Eur J Pharmacol 334 (1997) 55-60
30. Dinan T.G., and Scott L.V. Anatomy of melancholia: Focus on hypothalamic-pituitary-adrenal axis overactivity and the role of vasopressin. J Anat 207 (2005) 259-264
31. Scott L., and Dinan T. Vasopressin and the regulation of hypothalamic-pituitary-adrenal axis function: Implications for the pathophysiology of depression. Life Sci 62 (1998) 1985-1998
32. Gutkowska J., Jankowski M., Lambert C., et al. Oxytocin releases atrial natriuretic peptide by combining with oxytocin receptors in the heart. Proc Natl Acad Sci U S A 94 (1997) 11704-11709
33. Zenteno-Savin T., Sada-Ovalle I., Ceballos G., et al. Effects of arginine vasopressin in the heart are mediated by specific intravascular endothelial receptors. Eur J Pharmacol 410 (2000) 15-23
34. Boarder M., Weisman G., Turner J., et al. G protein-coupled P2 purinoceptors: From molecular biology to functional responses. Trends Pharmacol Sci 16 (1995) 133-139
35. Mei Q., and Liang B. P2 purinergic receptor activation enhances cardiac contractility in isolated rat and mouse hearts. Am J Physiol Heart Circ Physiol 281 (2001) H334-H341
36. Nadal M. Secretory rhythm of vasopressin in healthy subjects with inversed sleep-wake cycle: Evidence for the existence of an intrinsic regulation. Eur J Endocrinol 134 (1996) 174-176
37. Cohn J., Tristani F., and Khatri I. Systemic vasoconstrictor and renal vasodilator effects of PLV-2 (octapressin) in man. Circulation 38 (1968) 151-157
38. Lenz K., Druml W., Kleinberger G., et al. Enhancement of renal function with ornipressin in a patient with decompensated cirrhosis. Gut 26 (1985) 1385-1386
39. Nilsson G., Lindblom P., Ohlin M., et al. Pharmacokinetics of terlipressin after single IV doses to healthy volunteers. Drugs Exp Clin Res 16 (1990) 307-314
40. Ertmer C., Rehberg S., and Westphal M. Vasopressin analogues in the treatment of shock states: potential pitfalls. Best Pract Res Clin Anaesthesiol 22 (2008) 393-406
41. Singer M. Arginine vasopressin vs. terlipressin in the treatment of shock states. Best Pract Res Clin Anaesthesiol 22 (2008) 359-368
42. Kiszka-Kanowitz M., Henriksen J., Hansen E., et al. Effect of terlipressin on blood volume distribution in patients with cirrhosis. Scand J Gastroenterol 39 (2004) 486-492
43. Blei A., Groszmann R., Gusberg R., et al. Comparison of vasopressin and triglycyl-lysine vasopressin on splanchnic and systemic hemodynamics in dogs. Dig Dis Sci 25 (1980) 688-694
44. Hansen E., Strandberg C., Højgaard L., et al. Splanchnic haemodynamics after intravenous terlipressin in anaesthetised healthy pigs. J Hepatol 30 (1999) 503-510
45. Fast track designation for terlipressin in type 1 hepatorenal syndrome. Pharmaceutical News (2005 Apr 20). http://www.news-medical.net/news/2005/04/20/9386.aspx Accessed April 20, 2009
46. Richardson D., and Robinson A. Desmopressin. Ann Intern Med 103 (1985) 228-239
47. Mannucci P., Aberg M., Nilsson I., et al. Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs. Br J Haematol 30 (1975) 81-93
48. Mannucci P., Ruggeri Z., Pareti F., et al. 1-deamino-8-D-arginine vasopressin: A new pharmacological approach to the management of haemophilia and von Willebrands' diseases. Lancet 1 (1977) 869-872
49. Cash J., Gader A., and da Costa J. The release of plasminogen activator and factor VIII to lysine vasopressin, arginine vasopressin, I-desamino-8-D-argnine vasopressin, angiotensin and oxytocin in man. Br J Haematol 27 (1974) 373-374
50. Cattaneo M., Harris A.S., Stromberg U., et al. The effect of desmopressin on reducing blood loss in cardiac surgery-A meta-analysis of double-blind, placebo-controlled trials. Thromb Haemost 74 (1995) 1064-1070
51. Sadler J.E., Budde U., Eikenboom J.C., et al. Update on the pathophysiology and classification of von Willebrand disease: A report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 4 (2006) 2103-2114
52. Franchini M. The use of desmopressin as a hemostatic agent: A concise review. Am J Hematol 82 (2007) 731-735
53. Farmakis D., Filippatos G., Kremastinos D.T., et al. Vasopressin and vasopressin antagonists in heart failure and hyponatremia. Curr Heart Fail Rep 5 (2008) 91-96
54. Serradeil-Le Gal C., Lacour C., Valette G., et al. Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist. J Clin Invest 98 (1996) 2729-2738
55. Mitchell S., and Hunter J. Vasopressin and its antagonists: What are their roles in acute medical care?. Br J Anaesth 99 (2007) 154-158
56. Decaux G. Long-term treatment of patients with inappropriate secretion of antidiuretic hormone by the vasopressin receptor antagonist conivaptan, urea, or furosemide. Am J Med 110 (2001) 582-584
57. Gross P. Treatment of hyponatremia. Intern Med 47 (2008) 885-891
58. Finley J.J., Konstam M.A., and Udelson J.E. Arginine vasopressin antagonists for the treatment of heart failure and hyponatremia. Circulation 118 (2008) 410-421
59. Decaux G., Soupart A., and Vassart G. Non-peptide arginine-vasopressin antagonists: The vaptans. Lancet 371 (2008) 1624-1632
60. Bichet D.G. Nephrogenic diabetes insipidus. Adv Chronic Kidney Dis 13 (2006) 96-104
61. Spanakis E., Milord E., and Gragnoli C. AVPR2 variants and mutations in nephrogenic diabetes insipidus: Review and missense mutation significance. J Cell Physiol 217 (2008) 605-617
62. Birnbaumer M. The V2 vasopressin receptor mutations and fluid homeostasis. Cardiovasc Res 51 (2001) 409-415
63. Peters H., Robben J., Deen P., et al. Water in health and disease: New aspects of disturbances in water metabolism. Neth J Med 65 (2007) 325-332
64. Morello C., Cranmer L., and Spector D. Suppression of murine cytomegalovirus (MCMV) replication with a DNA vaccine encoding MCMV M84 (a homolog of human cytomegalovirus pp65). J Virol 74 (2000) 3696-3708
65. Bartter F.C., and Schwartz W.B. The syndrome of inappropriate secretion of antidiuretic hormone. Am J Med 42 (1967) 790-806
66. Schwartz W., Bennett W., Curelop S., et al. A syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone. Am J Med 23 (1957) 529-542
67. Kendler K.S., Weitzman R.E., and Fisher D.A. The effect of pain on plasma arginine vasopressin concentrations in man. Clin Endocrinol (Oxf) 8 (1978) 89-94
68. Moritz M., and Ayus J. The syndrome of inappropriate antidiuresis. N Engl J Med 357 (2007) 942
69. Forrest J.J., Cox M., Hong C., et al. Superiority of demeclocycline over lithium in the treatment of chronic syndrome of inappropriate secretion of antidiuretic hormone. N Engl J Med 298 (1978) 173-177
70. White M., and Fetner C. Treatment of the syndrome of inappropriate secretion of antidiuretic hormone with lithium carbonate. N Engl J Med 292 (1975) 390-392
71. Juurlink D., Mamdani M., Kopp A., et al. Drug-induced lithium toxicity in the elderly: A population-based study. J Am Geriatr Soc 52 (2004) 794-798
72. Oghlakian G., and Klapholz M. Vasopressin and vasopressin receptor antagonists in heart failure. Cardiol Rev 17 (2009) 10-15
73. Ghali J., Koren M., Taylor J., et al., Conivaptan study group. Efficacy and safety of oral Conivaptan: A V1a/V2 vasopressin receptor antagonist, assessed in a randomized placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab 91 (2006) 2145-2152
74. Schrier R., Gross P., Gheorghiade M., et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 355 (2006) 2099-2112
75. Lee C., Watkins M., Patterson J., et al. Vasopressin: A new target for the treatment of heart failure. Am Heart J 146 (2003) 9-18
76. Bakris G., Kusmirek S., Smith A., et al. Calcium antagonism abolishes the antipressor action of vasopressin (V1) receptor antagonism. Am J Hypertens 10 (1997) 1153-1158
77. Francis G. Neuroendocrine activity in congestive heart failure. Am J Cardiol 66 (1990) 33D-38D discussion 38D-39D
78. Gavras H. Role of vasopressin in clinical hypertension and congestive cardiac failure: Interaction with the sympathetic nervous system. Clin Chem 37 (1991) 1828-1830
79. Rouleau J., Packer M., Moyé L., et al. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: Effect of captopril. J Am Coll Cardiol 24 (1994) 583-591
80. Goldsmith S., Francis G., Levine T., et al. Impaired response of plasma vasopressin to orthostatic stress in patients with congestive heart failure. J Am Coll Cardiol 2 (1983) 1080-1083
81. Szatalowicz V., Arnold P., Chaimovitz C., et al. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N Engl J Med 305 (1981) 263-266
82. Gheorghiade M., Rossi J., Cotts W., et al. Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial. Arch Intern Med 167 (2007) 1998-2005
83. Khokhar A., Slater J., Ma J., et al. The cardiovascular effect of vasopressin in relation to its plasma concentration in man and its relevance to high blood pressure. Clin Endocrinol (Oxf) 13 (1980) 259-266
84. Gavras H., Hatzinikolaou P., North W., et al. Interaction of the sympathetic nervous system with vasopressin and renin in the maintenance of blood pressure. Hypertension 4 (1982) 400-405
85. Gheorghiade M., Niazi I., Ouyang J., et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: Results from a double-blind, randomized trial. Circulation 107 (2003) 2690-2696
86. Gheorghiade M., Gattis W., O'Connor C., et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: A randomized controlled trial. JAMA 291 (2004) 1963-1971
87. Gheorghiade M., Konstam M., Burnett J.J., et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The EVEREST Clinical Status Trials. JAMA 297 (2007) 1332-1343
88. Konstam M., Gheorghiade M., Burnett J.J., et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST Outcome Trial. JAMA 297 (2007) 1319-1331
89. Soupart A., Gross P., Legros J., et al. Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist. Clin J Am Soc Nephrol 1 (2006) 1154-1160
90. Ginès P., Wong F., Watson H., et al. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: A randomized trial. Hepatology 48 (2008) 204-213
91. Abraham W., Shamshirsaz A., Mefann K., et al. Aquaretic effect of Lixivaptan, an oral, non-peptide, selective V2-receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients. J Am Coll Cardiol 47 (2006) 1615-1621
92. Wong F., Blei A., Blendis L., et al. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: A multicenter, randomized, placebo-controlled trial. Hepatology 37 (2003) 182-191
93. Zelster D., Rosansky S., VanRensburg H., et al. Assessment of the efficacy and safety of intravenous Conivaptan in euvolemic and hypervolemic hyponatremia. Am J Nephrol 27 (2007) 447-457
94. Gheorghiade M., Abraham W., Albert N., et al. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: An analysis from the OPTIMIZE-HF registry. Eur Heart J 28 (2007) 980-988
95. Gheorghiade M., Orlandi C., Burnett J., et al. Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). J Card Fail 11 (2005) 260-269
96. Bishara B., Shiekh H., Karram T., et al. Effects of novel vasopressin receptor antagonists on renal function and cardiac hypertrophy in rats with experimental congestive heart failure. J Pharmacol Exp Ther 326 (2008) 414-422
97. Tahara A., Saito M., Sugimoto T., et al. AVP-induced mitogenic responses of Chinese hamster ovary cells expressing human V1A or V1B receptors. Pflugers Arch 437 (1999) 219-226
98. Tahara A., Saito M., Tsukada J., et al. Vasopressin increases vascular endothelial growth factor secretion from human vascular smooth muscle cells. Eur J Pharmacol 368 (1999) 89-94
99. Tahara A., Tomura Y., Wada K., et al. Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1A and V2 receptor antagonist, in vitro and in vivo. J Pharmacol Exp Ther 282 (1997) 301-308
100. Tahara A., Tsukada J., Ishii N., et al. Comparison of vasopressin binding sites in human uterine and vascular smooth muscle cells. Eur J Pharmacol 378 (1999) 137-142
101. Tahara A., Tomura Y., Wada K., et al. Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced hyperplasia and hypertrophy of cultured vascular smooth-muscle cells. J Cardiovasc Pharmacol 30 (1997) 759-766
102. Nakamura Y., Haneda T., Osaki J., et al. Hypertrophic growth of cultured neonatal rat heart cells mediated by vasopressin V(1A) receptor. Eur J Pharmacol 391 (2000) 39-48
103. Udelson J., Smith W., Hendrix G., et al. Acute hemodynamic effects of Conivaptan, a dual V1a and V2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 104 (2001) 2417-2423
104. Udelson J., Orlandi C., Ouyang J., et al. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial. J Am Coll Cardiol 52 (2008) 1540-1545
105. Russell S.D., Selaru P., Pyne D.A., et al. Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopressin ANtagonist in CHF patients undergoing Exercise) trial. Am Heart J 145 (2003) 179-186
106. Udelson J., McGrew F., Flores E., et al. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. J Am Coll Cardiol 49 (2007) 2151-2159
107. Bichet D., Razi M., Lonergan M., et al. Hemodynamic and coagulation responses to 1-desamino[8-D-arginine] vasopressin in patients with congenital nephrogenic diabetes insipidus. N Engl J Med 318 (1988) 881-887
108. Robertson J., Lillicrap D., and James P. von Willebrand Disease. Pediatr Clin North Am 55 (2008) 377-392
109. Mannucci P., Remuzzi G., Pusineri F., et al. Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. N Engl J Med 308 (1983) 8-12
110. Viganò G., Mannucci P., Lattuada A., et al. Subcutaneous desmopressin (DDAVP) shortens the bleeding time in uremia. Am J Hematol 31 (1989) 32-35
111. Shapiro M., and Kelleher S. Intranasal deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. Am J Nephrol 4 (1984) 260-261
112. Mannucci P.M., Vicente V., Vianello L., et al. Controlled trial of desmopressin in liver cirrhosis and other conditions associated with a prolonged bleeding time. Blood 67 (1986) 1148-1153
113. Burroughs A., Matthews K., Qadiri M., et al. Desmopressin and bleeding time in patients with cirrhosis. Br Med J (Clin Res Ed) 291 (1985) 1377-1381
114. López P., Otaso J., Alvarez D., et al. Hemostatic and hemodynamic effects of vasopressin analogue DDAVP in patients with cirrhosis. Acta Gastroenterol Latinoam 27 (1997) 59-62
115. Cattaneo M., Tenconi P., Alberca I., et al. Subcutaneous desmopressin (DDAVP) shortens the prolonged bleeding time in patients with liver cirrhosis. Thromb Haemost 64 (1990) 358-360
116. Sheridan D., Card R., Pinilla J., et al. Use of desmopressin acetate to reduce blood transfusion requirements during cardiac surgery in patients with acetylsalicylic-acid-induced platelet dysfunction. Can J Surg 37 (1994) 33-36
117. Gratz I., Koehler J., Olsen D., et al. The effect of desmopressin acetate on postoperative hemorrhage in patients receiving aspirin therapy before coronary artery bypass operations. J Thorac Cardiovasc Surg 104 (1992) 1417-1422
118. Kobrinsky N.L., Letts R.M., Patel L.R., et al. 1-Desamino-8-D-arginine vasopressin (desmopressin) decreases operative blood loss in patients having Harrington rod spinal fusion surgery. A randomized, double-blinded, controlled trial. Ann Intern Med 107 (1987) 446-450
119. Cattaneo M., Lombardi R., Bettega D., et al. Shear-induced platelet aggregation is potentiated by desmopressin and inhibited by ticlopidine. Arterioscler Thromb 13 (1993) 393-397
120. Cattaneo M. The use of desmopressin in open-heart surgery. Haemophilia 14 suppl 1 (2008) 40-47
121. Flordal P., Ljungström K., Ekman B., et al. Effects of desmopressin on blood loss in hip arthroplasty. Controlled study in 50 patients. Acta Orthop Scand 63 (1992) 381-385
122. Rocha E., Llorens R., Paramo J.A., et al. Does desmopressin acetate reduce blood loss after surgery in patients on cardiopulmonary bypass?. Circulation 77 (1988) 1319-1323
123. Hackmann T., and Naiman S.C. Con: Desmopressin is not of value in the treatment of post-cardiopulmonary bypass bleeding. J Cardiothorac Vasc Anesth 5 (1991) 290-293
124. Ansell J., Klassen V., Lew R., et al. Does desmopressin acetate prophylaxis reduce blood loss after valvular heart operations?. A randomized, double-blind study. J Thorac Cardiovasc Surg 104 (1992) 117-123
125. Theroux M., Corddry D., Tietz A., et al. A study of desmopressin and blood loss during spinal fusion for neuromuscular scoliosis: A randomized, controlled, double-blinded study. Anesthesiology 87 (1997) 260-267
126. Alanay A., Acaroglu E., Ozdemir O., et al. Effects of deamino-8-D-arginine vasopressin on blood loss and coagulation factors in scoliosis surgery. A double-blind randomized clinical trial. Spine 24 (1999) 877-882
127. Guay J., Reinberg C., Poitras B., et al. A trial of desmopressin to reduce blood loss in patients undergoing spinal fusion for idiopathic scoliosis. Anesth Analg 75 (1992) 405-410
128. Karnezis T., Stulberg S., Wixson R., et al. The hemostatic effects of desmopressin on patients who had total joint arthroplasty. A double-blind randomized trial. J Bone Joint Surg Am 76 (1994) 1545-1550
129. Schött U., Sollén C., Axelsson K., et al. Desmopressin acetate does not reduce blood loss during total hip replacement in patients receiving dextran. Acta Anaesthesiol Scand 39 (1995) 592-598
130. Fremes S., Wong B., Lee E., et al. Metaanalysis of prophylactic drug treatment in the prevention of postoperative bleeding. Ann Thorac Surg 58 (1994) 1580-1588
131. Levi M., Cromheecke M., de Jonge E., et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: A meta-analysis of clinically relevant endpoints. Lancet 354 (1999) 1940-1947
132. Carless P., Henry D., Moxey A., et al. Desmopressin for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev (2004) CD001884
133. Döhler K., and Meyer M. Vasopressin analogues in the treatment of hepatorenal syndrome and gastrointestinal haemorrhage. Best Pract Res Clin Anaesthesiol 22 (2008) 335-350
134. Testo A., Wongseelashote S., Angus P., et al. Long-term outcome of patients treated with terlipressin for types 1 and 2 hepatorenal syndrome. J Gastroenterol Hepatol 23 (2007) 1535-1540
135. Sanyal A., Boyer T., Garcia-Tsao G., et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 134 (2008) 1360-1368
136. Ortega R., Ginès P., Uriz J., et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: Results of a prospective, nonrandomized study. Hepatology 36 (2002) 941-948
137. Moreau R., Durand F., Poynard T., et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: A retrospective multicenter study. Gastroenterology 122 (2002) 923-930
138. Neri S., Pulvirenti D., Malaguarnera M., et al. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Dig Dis Sci 53 (2008) 830-835
139. Solanki P., Chawla A., Garg R., et al. Beneficial effects of terlipressin in hepatorenal syndrome: A prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol 18 (2003) 152-156
140. Landry D., Levin H., Gallant E., et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 95 (1997) 1122-1125
141. O'Brien A., Wilson A., Sibbald R., et al. Temporal variation in endotoxin-induced vascular hyporeactivity in a rat mesenteric artery organ culture model. Br J Pharmacol 133 (2001) 351-360
142. Buckley J., Singer M., and Clapp L. Role of KATP channels in sepsis. Cardiovasc Res 72 (2006) 220-230
143. Sharshar T., and Annane D. Endocrine effects of vasopressin in critically ill patients. Best Pract Res Clin Anaesthesiol 22 (2008) 265-273
144. Lin I., Ma H., Lin A., et al. Low plasma vasopressin/norepinephrine ratio predicts septic shock. Am J Emerg Med 23 (2005) 718-724
145. Reid I. Role of vasopressin deficiency in the vasodilation of septic shock. Circulation 95 (1997) 1108-1110
146. Landry D.W., Levin H.R., Gallant E.M., et al. Vasopressin pressor hypersensitivity in vasodilatory septic shock. Crit Care Med 25 (1997) 1279-1282
147. Morales D., Madigan J., Cullinane S., et al. Reversal by vasopressin of intractable hypotension in the late phase of hemorrhagic shock. Circulation 100 (1999) 226-229
148. Errington M.L., and Rocha e Silva M.J. The secretion and clearance of vasopressin during the development of irreversible haemorrhagic shock. J Physiol 217 (1971) 43P-45P
149. Landry D., and Oliver J. The pathogenesis of vasodilatory shock. N Engl J Med 345 (2001) 588-595
150. Wilson M., Brackett D., Tompkins P., et al. Elevated plasma vasopressin concentrations during endotoxin and E. coli shock. Adv Shock Res 6 (1981) 15-26
151. Brackett D., Schaefer C., Tompkins P., et al. Evaluation of cardiac output, total peripheral vascular resistance, and plasma concentrations of vasopressin in the conscious, unrestrained rat during endotoxemia. Circ Shock 17 (1985) 273-284
152. Wilson M., Brackett D., Hinshaw L., et al. Vasopressin release during sepsis and septic shock in baboons and dogs. Surg Gynecol Obstet 153 (1981) 869-872
153. Wilson M., and Brackett D. Release of vasoactive hormones and circulatory changes in shock. Circ Shock 11 (1983) 225-234
154. Barrett L.K., Singer M., and Clapp L.H. Vasopressin: Mechanisms of action on the vasculature in health and in septic shock. Crit Care Med 35 (2007) 33-40
155. Russell J., Walley K., Singer J., et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 358 (2008) 877-887
156. Russell J., Walley K., Gordon A., et al. Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Crit Care Med 37 (2009) 811-818
157. O'Brien A., Clapp L., and Singer M. Terlipressin for norepinephrine-resistant septic shock. Lancet 359 (2002) 1209-1210
158. Leone M., Albanese J., Delmas A., et al. Terlipressin in catecholamine-resistant septic shock patients. Shock 22 (2004) 314-319
159. Morelli A., Rocco M., Conti G., et al. Effects of terlipressin on systemic and regional haemodynamics in catecholamine-treated hyperkinetic septic shock. Intensive Care Med 30 (2004) 597-604
160. Albanèse J., Leone M., Delmas A., et al. Terlipressin or norepinephrine in hyperdynamic septic shock: A prospective, randomized study. Crit Care Med 33 (2005) 1897-1902
161. Morelli A., Ertmer C., and Westphal M. Terlipressin in the treatment of septic shock: The earlier the better?. Best Pract Res Clin Anesthesiol 22 (2008) 317-321
162. Morelli A., Ertmer C., Lange M., et al. Continuous terlipressin infusion in patients with septic shock: Less may be best, and the earlier the better?. Intensive Care Med 33 (2007) 1669-1670
163. Meyer S., Gortner L., McGuire W., et al. Vasopressin in catecholamine-refractory shock in children. Anaesthesia 63 (2008) 228-234
164. Leone M., and Martin C. Role of terlipressin in the treatment of infants and neonates with catecholamine-resistant septic shock. Best Pract Res Clin Anesthesiol 22 (2008) 323-333
165. Choong K., and Kissoon N. Vasopressin in pediatric shock and cardiac arrest. Pediatr Crit Care Med 9 (2008) 372-379
166. Wolf A. Vasopressin in paediatric practice. Paediatr Anaesth 18 (2008) 579-581
167. Dellinger R., Levy M., Carlet J., et al. Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 34 (2008) 17-60
168. Lindner K.H., Haak T., Keller A., et al. Release of endogenous vasopressors during and after cardiopulmonary resuscitation. Heart 75 (1996) 145-150
169. Lindner K.H., Strohmenger H.U., Ensinger H., et al. Stress hormone response during and after cardiopulmonary resuscitation. Anesthesiology 77 (1992) 662-668
170. Lindner K.H., Prengel A.W., Pfenninger E.G., et al. Vasopressin improves vital organ blood flow during closed-chest cardiopulmonary resuscitation in pigs. Circulation 91 (1995) 215-221
171. Prengel A.W., Lindner K.H., and Keller A. Cerebral oxygenation during cardiopulmonary resuscitation with epinephrine and vasopressin in pigs. Stroke 27 (1996) 1241-1248
172. Wenzel V., Lindner K.H., Augenstein S., et al. Intraosseous vasopressin improves coronary perfusion pressure rapidly during cardiopulmonary resuscitation in pigs. Crit Care Med 27 (1999) 1565-1569
173. Wenzel V., Lindner K.H., Krismer A.C., et al. Repeated administration of vasopressin but not epinephrine maintains coronary perfusion pressure after early and late administration during prolonged cardiopulmonary resuscitation in pigs. Circulation 99 (1999) 1379-1384
174. Wenzel V., Lindner K.H., Prengel A.W., et al. Endobronchial vasopressin improves survival during cardiopulmonary resuscitation in pigs. Anesthesiology 86 (1997) 1375-1381
175. Wenzel V., Lindner K.H., Prengel A.W., et al. Vasopressin improves vital organ blood flow after prolonged cardiac arrest with postcountershock pulseless electrical activity in pigs. Crit Care Med 27 (1999) 486-492
176. Wenzel V., Lindner K.H., Krismer A.C., et al. Survival with full neurologic recovery and no cerebral pathology after prolonged cardiopulmonary resuscitation with vasopressin in pigs. J Am Coll Cardiol 35 (2000) 527-533
177. Aung K., and Htay T. Vasopressin for cardiac arrest: A systematic review and meta-analysis. Arch Int Med 165 (2005) 17-24
178. Nolan J., Deakin C., Soar J., et al. European Resuscitation Council guidelines for resuscitation 2005. Section 4. Adult advanced life support. Resuscitation 67 suppl 1 (2005) S39-S86
179. Wenzel V., Krismer A.C., Arntz H.R., et al. A comparison of vasopressin and epinephrine for out-of-hospital cardiopulmonary resuscitation. N Engl J Med 350 (2004) 105-113
180. Gueugniaud P.-Y., David J.-S., Chanzy E., et al. Vasopressin and epinephrine vs. epinephrine alone in cardiopulmonary resuscitation. N Engl J Med 359 (2008) 21-30
181. Mentzelopoulos S.D., Zakynthinos S.G., Tzoufi M., et al. Vasopressin, epinephrine, and corticosteroids for in-hospital cardiac arrest. Arch Int Med 169 (2009) 15-24
182. Mann K., Berg R.A., and Nadkarni V. Beneficial effects of vasopressin in prolonged pediatric cardiac arrest: A case series. Resuscitation 52 (2002) 149-156
183. Duncan J., Meaney P., Simpson P., et al. Vasopressin for in-hospital pediatric cardiac arrest: Results from the American Heart Association National Registry of Cardiopulmonary Resuscitation. Pediatr Crit Care Med 10 (2009) 191-195
184. 2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 112 (2005) IV1-203
185. Voelckel W.G., Lurie K.G., Lindner K.H., et al. Vasopressin improves survival after cardiac arrest in hypovolemic shock. Anesth Analg 91 (2000) 627-634
186. Voelckel W.G., Raedler C., Wenzel V., et al. Arginine vasopressin, but not epinephrine, improves survival in uncontrolled hemorrhagic shock after liver trauma in pigs. Crit Care Med 31 (2003) 1160-1165
187. Stadlbauer K.H., Wagner-Berger H.G., Raedler C., et al. Vasopressin, but not fluid resuscitation, enhances survival in a liver trauma model with uncontrolled and otherwise lethal hemorrhagic shock in pigs. Anesthesiology 98 (2003) 699-704
188. Sharma R.M., and Setlur R. Vasopressin in hemorrhagic shock. Anesth Analg 101 (2005) 833-834
189. Krismer A.C., Wenzel V., Voelckel W.G., et al. Employing vasopressin as an adjunct vasopressor in uncontrolled traumatic hemorrhagic shock. Three cases and a brief analysis of the literature. Anaesthesist 54 (2005) 220-224
190. Haas T., Voelckel W., Wiedermann F., et al. Successful resuscitation of a traumatic cardiac arrest victim in hemorrhagic shock with vasopressin: A case report and brief review of the literature. J Trauma 57 (2004) 177-179
191. Johnson K., Pearce F., Jeffreys N., et al. Impact of vasopressin on hemodynamic and metabolic function in the decompensatory phase of hemorrhagic shock. J Cardiothorac Vasc Anesth 20 (2006) 167-172
192. Wenzel V., Raab H., and Dunser M.W. Arginine vasopressin: A promising rescue drug in the treatment of uncontrolled haemorrhagic shock. Best Pract Res Clin Anaesthesiol 22 (2008) 299-316
193. Lienhart H., Wenzel V., Braun J., et al. Vasopressin for therapy of persistent traumatic hemorrhagic shock: The VITRIS.at study. Anaesthesist 56 (2007) 145-148
194. Lienhart H.G., Lindner K.H., and Wenzel V. Developing alternative strategies for the treatment of traumatic haemorrhagic shock. Curr Opin Crit Care 14 (2008) 247-253
195. Jochberger S., and Dunser M.W. Arginine vasopressin as a rescue vasopressor to treat epidural anaesthesia-induced arterial hypotension. Best Pract Res Clin Anaesthesiol 22 (2008) 383-391
196. Hopf H., Arand D., and Peters J. Sympathetic blockade by thoracic epidural anaesthesia suppresses renin release in response to hypotension, but activates the vasopressin system. Eur J Anaesthesiol 9 (1992) 63-69
197. Hopf H., Schlaghecke R., and Peters J. Sympathetic neural blockade by thoracic epidural anesthesia suppresses renin release in response to arterial hypotension. Anesthesiology 80 (1994) 992-999
198. Lange M., Ertmer C., and Westphal M. Vasopressin vs. terlipressin in the treatment of cardiovascular failure in sepsis. Intensive Care Med 34 (2008) 821-832
199. De Kock M., Laterre P., Andruetto P., et al. Ornipressin (Por 8): An efficient alternative to counteract hypotension during combined general/epidural anesthesia. Anesth Analg 90 (2000) 1301-1307
200. Vaquero Roncero L., Sánchez Montero F., and Muriel Villoria C. Effectiveness of epidural administration of saline solutions to prevent or treat postdural puncture headache. Rev Esp Anestesiol Reanim 51 (2004) 589-594
201. Boccara G., Ouattara A., Godet G., et al. Terlipressin versus norepinephrine to correct refractory arterial hypotension after general anesthesia in patients chronically treated with renin-angiotensin system inhibitors. Anesthesiology 98 (2003) 1338-1344
202. Braun E., Palin C., and Hogue C. Vasopressin during spinal anesthesia in a patient with primary pulmonary hypertension treated with intravenous epoprostenol. Anesth Analg 99 (2004) 36-37
203. Morelli A., Tritapepe L., Rocco M., et al. Terlipressin versus norepinephrine to counteract anesthesia-induced hypotension in patients treated with renin-angiotensin system inhibitors: Effects on systemic and regional hemodynamics. Anesthesiology 102 (2005) 12-19
204. Meersschaert K., Brun L., Gourdin M., et al. Terlipressin-ephedrine versus ephedrine to treat hypotension at the induction of anesthesia in patients chronically treated with angiotensin-converting enzyme inhibitors: A prospective, randomized, double-blinded, crossover study. Anesth Analg 94 (2002) 835-840
205. Eyraud D., Brabant S., Nathalie D., et al. Treatment of intraoperative refractory hypotension with terlipressin in patients chronically treated with an antagonist of the renin-angiotensin system. Anesth Analg 88 (1999) 980-984
206. Morales D., Garrido M., Madigan J., et al. A double-blind randomized trial: prophylactic vasopressin reduces hypotension after cardiopulmonary bypass. Ann Thorac Surg 75 (2003) 926-930
207. Schummer C., Wirsing M., and Schummer W. The pivotal role of vasopressin in refractory anaphylactic shock. Anesth Analg 107 (2008) 620-624
208. Schummer W., Schummer C., Wippermann J., et al. Anaphylactic shock: Is vasopressin the drug of choice?. Anesthesiology 101 (2004) 1025-1027
209. Argenziano M., Chen J.M., Choudhri A.F., et al. Management of vasodilatory shock after cardiac surgery: Identification of predisposing factors and use of a novel pressor agent. J Thorac Cardiovasc Surg 116 (1998) 973-980
210. Paparella D., Yau T., and Young E. Cardiopulmonary bypass induced inflammation: Pathophysiology and treatment. An update. Eur J Cardiothorac Surg 21 (2002) 232-244
211. Hoshikawa-Fujimura A., Auler Júnior J., Da Rocha T., et al. PAF-acether, superoxide anion and beta-glucuronidase as parameters of polymorphonuclear cell activation associated with cardiac surgery and cardiopulmonary bypass. Braz J Med Biol Res 22 (1989) 1077-1082
212. Kirklin J. Prospects for understanding and eliminating the deleterious effects of cardiopulmonary bypass. Ann Thorac Surg 51 (1991) 529-531
213. Singh Ranger G. Antidiuretic hormone replacement therapy to prevent or ameliorate vasodilatory shock. Med Hypotheses 59 (2002) 337-340
214. Wu W., Zbuzek V.K., and Bellevue C. Vasopressin release during cardiac operation. J Thorac Cardiovasc Surg 79 (1980) 83-90
215. Kuitunen A., Hynynen M., Salmenpera M., et al. Anaesthesia affects plasma concentrations of vasopressin, von Willebrand factor and coagulation factor VIII in cardiac surgical patients. Br J Anaesth 70 (1993) 173-180
216. Woods W.G., Forsling M.L., and Le Quesne L.P. Plasma arginine vasopressin levels and arterial pressure during open heart surgery. Br J Surg 76 (1989) 29-32
217. Argenziano M., Choudhri A., Oz M., et al. A prospective randomized trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placement. Circulation 96 (1997) II-286-II-290
218. Masetti P., Murphy S.F., and Kouchoukos N.T. Vasopressin therapy for vasoplegic syndrome following cardiopulmonary bypass. J Cardiac Surg 17 (2002) 485-489
219. Dunser M.W., Mayr A.J., Stallinger A., et al. Cardiac performance during vasopressin infusion in postcardiotomy shock. Intensive Care Med 28 (2002) 746-751
220. Dunser M.W., Mayr A.J., Ulmer H., et al. The effects of vasopressin on systemic hemodynamics in catecholamine-resistant septic and postcardiotomy shock: A retrospective analysis. Anesth Analg 93 (2001) 7-13
221. Overand P.T., and Teply J.F. Vasopressin for the treatment of refractory hypotension after cardiopulmonary bypass. Anesth Analg 86 (1998) 1207-1209
222. Mayr V.D., Wenzel V., Muller T., et al. Effects of vasopressin on left anterior descending coronary artery blood flow during extremely low cardiac output. Resuscitation 62 (2004) 229-235
223. Luckner G., Dunser M.W., Jochberger S., et al. Arginine vasopressin in 316 patients with advanced vasodilatory shock. Crit Care Med 33 (2005) 2659-2666
224. Shelly M.P., Greatorex R., Calne R.Y., et al. The physiological effects of vasopressin when used to control intra-abdominal bleeding. Intensive Care Med 14 (1988) 526-531
225. Sirinek K.R., and Thomford N.R. Isoproterenol in offsetting adverse effects of vasopressin in cirrhotic patients. Am J Surg 129 (1975) 130-136
226. Morales D.L., Gregg D., Helman D.N., et al. Arginine vasopressin in the treatment of 50 patients with postcardiotomy vasodilatory shock. Ann Thorac Surg 69 (2000) 102-106
227. Egi M., Bellomo R., Langenberg C., et al. Selecting a vasopressor drug for vasoplegic shock after adult cardiac surgery: A systematic literature review. Ann Thorac Surg 83 (2007) 715-723
228. Leone M., Charvet A., Delmas A., et al. Terlipressin: A new therapeutic for calcium-channel blockers overdose. J Crit Care 20 (2005) 114-115
229. Zuidema X., Dünser M., Wenzel V., et al. Terlipressin as an adjunct vasopressor in refractory hypotension after tricyclic antidepressant intoxication. Resuscitation 72 (2007) 319-323
230. Salluh J., Martins G., Santino M., et al. Early use of terlipressin in catecholamine-resistant shock improves cerebral perfusion pressure in severe traumatic brain injury. Acta Anaesthesiol Scand 51 (2007) 505-508
231. Kusano E., Tian S., Umino T., et al. Arginine vasopressin inhibits interleukin-1 beta-stimulated nitric oxide and cyclic guanosine monophosphate production via the V1 receptor in cultured rat vascular smooth muscle cells. J Hypertens 15 (1997) 627-632
232. Umino T., Kusano E., Muto S., et al. AVP inhibits LPS- and IL-1beta-stimulated NO and cGMP via V1 receptor in cultured rat mesangial cells. Am J Physiol 276 (1999) F433-F441
233. Nambi P., Whitman M., Gessner G., et al. Vasopressin-mediated inhibition of atrial natriuretic factor-stimulated cGMP accumulation in an established smooth muscle cell line. Proc Natl Acad Sci U S A 83 (1986) 8492-8495
234. Wakatsuki T., Nakaya Y., and Inoue I. Vasopressin modulates K(+)-channel activities of cultured smooth muscle cells from porcine coronary artery. Am J Physiol 263 (1992) H491-H496
235. Wakatsuki T., Nakaya Y., Miyoshi Y., et al. Effects of vasopressin on ATP-sensitive and Ca(2+)-activated K+ channels of coronary arterial smooth muscle cells. Jpn J Pharmacol 58 suppl 2 (1992) 339P
236. Malay M.B., Ashton Jr. R.C., Landry D.W., et al. Low-dose vasopressin in the treatment of vasodilatory septic shock. J Trauma 47 (1999) 699-703
237. Bartelstone H., and Nasmyth P. Vasopressin potentiation of catecholamine actions in dog, rat, cat, and rat aortic strip. Am J Physiol 208 (1965) 754-762
238. Medina P., Acuña A., Martínez-León J., et al. Arginine vasopressin enhances sympathetic constriction through the V1 vasopressin receptor in human saphenous vein. Circulation 97 (1998) 865-870
239. Buijk S., and Bruining H. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 98 (1998) 187
240. Hayoz D., Bizzini G., Noel B., et al. Effect of SR 49059, a V1a vasopressin receptor antagonist, in Raynaud's phenomenon. Rheumatology 39 (2000) 1132-1138
241. Akerlund M., Bossmar T., Brouard R., et al. Receptor binding of oxytocin and vasopressin antagonists and inhibitory effects on isolated myometrium from preterm and term pregnant women. Br J Obstet Gynaecol 106 (1999) 1047-1053
242. Steinwall M., Bossmar T., Brouard R., et al. The effect of relcovaptan (SR 49059), an orally active vasopressin V1a receptor antagonist, on uterine contractions in preterm labor. Gynecol Endocrinol 20 (2005) 104-109
243. Steinwall M., Bossmar T., Gaud C., et al. Inhibitory effects of SR 49059 on oxytocin and vasopressin-induced uterine contractions in non-pregnant women. Acta Obstet Gynecol Scand 83 (2004) 12-18
244. Brouard R., Bossmar T., Fournie-Lloret D., et al. Effect of SR49059, an orally active V1a vasopressin receptor antagonist, in the prevention of dysmenorrhoea. BJOG 107 (2000) 614-619
245. Takeda T., Sawada S., Takeda S., et al. The effects of V2 antagonist (OPC-31260) on endolymphatic hydrops. Hear Res 182 (2003) 9-18
246. Sonino N., Boscaro M., and Fallo F. Pharmacologic management of Cushing syndrome: New targets for therapy. Treat Endocrinol 4 (2005) 87-94
247. Ali F., Guglin M., Vaitkevicius P., et al. Therapeutic potential of vasopressin receptor antagonists. Drugs 67 (2007) 847-858
248. Doggrell S. Do vasopressin receptor type 2 antagonists have therapeutic potential in polycystic kidney diseases?. Expert Opin Investig Drugs 13 (2004) 431-434
249. Gattone V.N., Wang X., Harris P., et al. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 9 (2003) 1323-1326
250. Greenberg A., and Verbalis J.G. Vasopressin receptor antagonists. Kidney Int 69 (2006) 2124-2130
251. Gross P. Polycystic kidney disease: Will it become treatable?. Pol Arch Med Wewn 118 (2008) 298-301
252. Mastorakos G., Pavlatou M.G., and Mizamtsidi M. The hypothalamic-pituitary-adrenal and the hypothalamic- pituitary-gonadal axes interplay. Pediatr Endocrinol Rev 3 suppl 1 (2006) 172-181
253. Torres V.E. Vasopressin antagonists in polycystic kidney disease. Kidney Int 68 (2005) 2405-2418
254. Torres V.E. Role of vasopressin antagonists. Clin J Am Soc Nephrol 3 (2008) 1212-1218
255. Torres V.E. Vasopressin antagonists in polycystic kidney disease. Sem Nephrol 28 (2008) 306-317
256. Lacheretz F., Barbier A., Serradeil-Le Gal C., et al. Effect of SR121463, a selective non-peptide vasopressin V2 receptor antagonist, in a rabbit model of ocular hypertension. J Ocul Pharmacol Ther 16 (2000) 203-216
257. Naito A., Kurasawa T., Ohtake Y., et al. The effects of several vasopressin receptor antagonists on normal intraocular pressure and the intraocular distribution of vasopressin receptor subtypes. Biol Pharm Bull 25 (2002) 251-255
258. Nishihashi T., Trandafir C., Wang A., et al. Enhanced reactivity to vasopressin in rat basilar arteries during vasospasm after subarachnoid hemorrhage. Eur J Pharmacol 513 (2005) 93-100
259. Trandafir C., Nishihashi T., Wang A., et al. Participation of vasopressin in the development of cerebral vasospasm in a rat model of subarachnoid haemorrhage. Clin Exp Pharmacol Physiol 31 (2004) 261-266
260. Rabinstein A.A. Vasopressin antagonism: Potential impact on neurologic disease. Clin Neuropharmacol 29 (2006) 87-93
261. Molnár A., Varga C., Berkó A., et al. Prevention of hypoxic brain oedema by the administration of vasopressin receptor antagonist OPC-31260. Prog Brain Res 170 (2008) 519-525
262. Caldwell H.K., Lee H.-J., Macbeth A.H., et al. Vasopressin: Behavioral roles of an "original" neuropeptide. Prog Neurobiol 84 (2008) 1-24
263. Heinrichs M., and Domes G. Neuropeptides and social behaviour: Effects of oxytocin and vasopressin in humans. Prog Brain Res 170 (2008) 337-350
264. Hodgson R.A., Higgins G.A., Guthrie D.H., et al. Comparison of the V1b antagonist, SSR149415, and the CRF1 antagonist, CP-154,526, in rodent models of anxiety and depression. Pharmacol Biochem Behav 86 (2007) 431-440
265. Keck M.E. Corticotropin-releasing factor, vasopressin and receptor systems in depression and anxiety. Amino Acids 31 (2006) 241-250
266. Landgraf R. The involvement of the vasopressin system in stress-related disorders. CNS Neurol Disord Drug Targets 5 (2006) 167-179
267. Landgraf R., Kessler M.S., Bunck M., et al. Candidate genes of anxiety-related behavior in HAB/LAB rats and mice: Focus on vasopressin and glyoxalase-I. Neurosci Biobehav Rev 31 (2007) 89-102
268. Simon N.G., Guillon C., Fabio K., et al. Vasopressin antagonists as anxiolytics and antidepressants: recent developments. Recent Pat CNS Drug Discov 3 (2008) 77-93
269. Surget A., and Belzung C. Involvement of vasopressin in affective disorders. Eur J Pharmacol 583 (2008) 340-349
270. Veenema A.H., and Neumann I.D. Central vasopressin and oxytocin release: Regulation of complex social behaviours. Prog Brain Res 170 (2008) 261-276
271. Blanchard R.J., Griebel G., Farrokhi C., et al. AVP V1b selective antagonist SSR149415 blocks aggressive behaviors in hamsters. Pharmacol Biochem Behav 80 (2005) 189-194
272. Griebel G., Simiand J., Serradeil-Le Gal C., et al. Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proc Natl Acad Sci U S A 99 (2002) 6370-6375
273. Griebel G., Simiand J., Stemmelin J., et al. The vasopressin V1b receptor as a therapeutic target in stress-related disorders. Curr Drug Targets CNS Neurol Disord 2 (2003) 191-200
274. Griebel G., Stemmelin J., Gal C.S.-L., et al. Non-peptide vasopressin V1b receptor antagonists as potential drugs for the treatment of stress-related disorders. Curr Pharm Des 11 (2005) 1549-1559
275. Overstreet D.H., and Griebel G. Antidepressant-like effects of the vasopressin V1b receptor antagonist SSR149415 in the Flinders Sensitive Line rat. Pharm Biochem Behav 82 (2005) 223-227
276. Serradeil-Le Gal C., Derick S., Brossard G., et al. Functional and pharmacological characterization of the first specific agonist and antagonist for the V1b receptor in mammals. Stress 6 (2003) 199-206
277. Dempster E.L., Burcescu I., Wigg K., et al. Evidence of an association between the vasopressin V1b receptor gene (AVPR1B) and childhood-onset mood disorders. Arch Gen Psych 64 (2007) 1189-1195
278. Cartotto R., McGibney K., Smith T., et al. Vasopressin for the septic burn patient. Burns 33 (2007) 441-451
279. Bunker N., and Higgins D. Peripheral administration of vasopressin for catecholamine-resistant hypotension complicated by skin necrosis. Crit Care Med 34 (2006) 935
280. Dünser M., Mayr A., Tür A., et al. Ischemic skin lesions as a complication of continuous vasopressin infusion in catecholamine-resistant vasodilatory shock: Incidence and risk factors. Crit Care Med 31 (2003) 1394-1398
281. Kim E., Lee S., Byun S., et al. Skin necrosis after a low-dose vasopressin infusion through a central venous catheter for treating septic shock. Korean J Intern Med 21 (2006) 287-290
282. Kahn J., Kress J., and Hall J. Skin necrosis after extravasation of low-dose vasopressin administered for septic shock. Crit Care Med 30 (2002) 1899-1901
283. Dunser M.W., Mayr A.J., Ulmer H., et al. Arginine vasopressin in advanced vasodilatory shock: A prospective, randomized, controlled study. Circulation 107 (2003) 2313-2319
284. van Haren F.M.P., Rozendaal F.W., and van der Hoeven J.G. The effect of vasopressin on gastric perfusion in catecholamine-dependent patients in septic shock. Chest 124 (2003) 2256-2260
285. Patel B.M., Chittock D.R., Russell J.A., et al. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 96 (2002) 576-582
286. Klinzing S., Simon M., Reinhart K., et al. High-dose vasopressin is not superior to norepinephrine in septic shock. Crit Care Med 31 (2003) 2646-2650
287. Russell J.A. Vasopressin in septic shock. Crit Care Med 35 (2007) S609-S615
288. Asfar P., Bracht H., and Radermacher P. Impact of vasopressin analogues on the gut mucosal microcirculation. Best Pract Res Clin Anaesthesiol 22 (2008) 351-358
289. Obritsch M.D., Jung R., Fish D.N., et al. Effects of continuous vasopressin infusion in patients with septic shock. Ann Pharmacother 38 (2004) 1117-1122
290. Holmes C.L., Walley K.R., Chittock D.R., et al. The effects of vasopressin on hemodynamics and renal function in severe septic shock: A case series. Intensive Care Med 27 (2001) 1416-1421
291. Dünser M., Fries D., Schobersberger W., et al. Does arginine vasopressin influence the coagulation system in advanced vasodilatory shock with severe multiorgan dysfunction syndrome?. Anesth Analg 99 (2004) 201-206
292. Dunser M.W., and Westphal M. Arginine vasopressin in vasodilatory shock: Effects on metabolism and beyond. Curr Opin Anaesthesiol 21 (2008) 122-127